Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Phys Rev Lett ; 129(19): 199702, 2022 11 04.
Article in English | MEDLINE | ID: mdl-36399762
2.
Phys Rev Lett ; 127(19): 197001, 2021 Nov 05.
Article in English | MEDLINE | ID: mdl-34797154

ABSTRACT

In superconductors the Anderson-Higgs mechanism allows for the existence of a collective amplitude (Higgs) mode which can couple to eV light mainly in a nonlinear Raman-like process. The experimental nonequilibrium results on isotropic superconductors have been explained going beyond the BCS theory including the Higgs mode. Furthermore, in anisotropic d-wave superconductors strong interaction effects with other modes are expected. Here we calculate the Raman contribution of the Higgs mode from a new perspective, including many-body Higgs oscillations effects and their consequences in conventional, spontaneous Raman spectroscopy. Our results suggest a significant contribution to the intensity of the A_{1g} symmetry Raman spectrum in d-wave superconductors. In order to test our theory, we predict the presence of measurable characteristic oscillations in THz quench-optical probe time-dependent reflectivity experiments.

3.
J Eur Acad Dermatol Venereol ; 33(9): 1768-1774, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31025401

ABSTRACT

BACKGROUND: Comedogenesis is defined as the process of the development of a new comedo, which is of great importance for the understanding of acne. OBJECTIVE: To evaluate the formation and evolution of acne lesions from clinically unaffected skin of patients with mild-moderate acne to characterize the morphological changes and natural resolution by means of in vivo reflectance confocal microscopy (RCM) and dynamic optical coherence tomography (D-OCT). METHODS: Ten patients with mild-moderate acne, not assuming any topical or systemic therapy, comprised between 12 and 30 years of age, were recruited. A target area of 4 × 4 mm of the face, without acne lesions at baseline, was selected. A set of standardized clinical pictures, RCM and D-OCT images were acquired weekly for 6 weeks and evaluated. RESULTS: Seventy full sets of clinical, RCM and D-OCT images were analysed. The appearance of acne lesion is preceded by an increase of large bright follicles in the area corresponding to infundibular keratinization, followed by increment of inflammation parameter, such as increased of small bright cells upon RCM and vascular network upon D-OCT, which return to normal after the resolution of acute inflammation. CONCLUSION: Acne skin dynamics is complex and seems characterized by the early increase in the number of dysmorphic pilosebaceous units and the hyperkeratinization of the acroinfundibulum of the pilosebaceous duct prior to the occurrence of inflammatory events around the follicle. The processes of hyperkeratinization and inflammatory phenomena may generate a pathologic vicious cycle, which characterizes acne through progressive worsening and a self-sustainment mechanism.


Subject(s)
Acne Vulgaris/diagnostic imaging , Microscopy, Confocal , Tomography, Optical Coherence , Acne Vulgaris/pathology , Adolescent , Adult , Child , Disease Progression , Humans , Longitudinal Studies , Severity of Illness Index
5.
G Ital Dermatol Venereol ; 150(6): 643-8, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26513041

ABSTRACT

AIM: Treatment of plantar and periungueal warts (so called "difficult-to-treat" warts, DTW) and external genital warts (EGW) remains unsatisfactory. Medical or invasive procedures are partially effective and/or painful. Furthermore recurrences rates after treatments are still a relevant problem for all the available therapies. Nitric-zinc complex is a solution for topical application containing nitric acid, zinc, copper and organic acids able to induce a caustic effect of the wart trough mummification and proteins denaturation/coagulation action. Nitric-zinc complex has been shown to be an effective and well tolerated treatment of common warts. METHODS: We evaluated in a prospective open label 4-centre trial, the efficacy and local tolerability of nitric-zinc complex in the treatment of EGW and DTW. A total of 37 immunocompetent subjects (20 men and 17 women; mean age: 45 years) with single or multiple lesions, were enrolled, after their informed consent. A total of 30 subjects had EGW, 2 subjects had plantar warts, 2 warts of the hand and 3 periungueal lesions. Nitric-zinc aqueous solution was applied topically using a 30 mL capillary tube over the lesions until a whitening/yellowish reaction appeared. A second (or more, if needed) application was performed at two-week interval until a complete clinical cure rate was observed. Primary outcome of the study was the clinical evaluation with picture documentation of the evolution of lesions classified as total cure, partial disappearance or no effect. Topical tolerability was evaluated through patient's reported adverse events. RESULTS: All subjects completed the study. A complete cure of lesions was observed in 31 subjects (90%) after one and up to four applications. Three patients with EGW (8%) showed a partial disappearance of lesions and one (2%) subject was no responder to four nitric-zinc complex applications. The product was well tolerated. No serious adverse events were observed or recorded. CONCLUSION: Nitric-zinc complex topical solution has shown to be an effective and well tolerated treatment of EGW and "difficult-to-treat" warts with a 90% of subjects with a total cure after one or up to four applications. A total or partial response was observed in 99% of the subjects. Nitric-zinc complex could be considered an easy-to-use effective treatment strategy of "difficult-to-treat" warts and external genital warts. Additional studies comparing nitric-zinc complex to other strategies are warranted.


Subject(s)
Dermatologic Agents/therapeutic use , Warts/drug therapy , Administration, Topical , Adult , Condylomata Acuminata/drug therapy , Dermatologic Agents/administration & dosage , Dermatologic Agents/adverse effects , Female , Foot Dermatoses/drug therapy , Genital Diseases, Female/drug therapy , Genital Diseases, Male/drug therapy , Hand Dermatoses/drug therapy , Humans , Immunocompetence , Male , Middle Aged , Nitric Acid/administration & dosage , Nitric Acid/adverse effects , Nitric Acid/therapeutic use , Prospective Studies , Solutions , Treatment Outcome , Zinc/administration & dosage , Zinc/adverse effects , Zinc/therapeutic use
6.
Minerva Pediatr ; 66(4): 307-11, 2014 Aug.
Article in English | MEDLINE | ID: mdl-25198568

ABSTRACT

Atopic eczema (AE) is a skin disease very common in paediatric population and face region is commonly involved. AE of the face represents a therapeutic challenge limiting the use, especially for long periods, of corticosteroid topical products due to the high risk of atrophic skin changes. Skin barrier alterations and reduction of innate immune mechanisms (reduced levels of anti-microbial peptides) are now considered the hallmarks of AE. Therefore emollient and barrier repair therapies with topical steroid-free substances could be an alternative or an adjuvant strategy in managing AE especially for the face. A non-steroidal, anti-inflammatory moisturizing cream with barrier repair actions, containing rhamnosoft, ceramides and L-isoleucine (ILE) (Nutratopic pro-AMP) has been recently developed for the specific treatment of AE of the face. We report a series of 6 pediatric cases (2 female and 4 male, age from 6 months to 4 years) with facial eczema in children treated with pro-AMP cream for two/four weeks as single treatment, applied twice daily in the affected area with photograph documentation (baseline and after treatment). Pictures of the skin lesions at baseline and after treatment were taken in all cases using a high-definition digital camera. Pro-AMP cream use was associated with a clinical relevant improvement of all signs of eczema. The product was well tolerated. This case series document the clinical efficacy of a barrier repair therapy cream containing rhamnosoft, ceramides and iso-leucine in the treatment of atopic eczema of the face.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Ceramides/therapeutic use , Dermatitis, Atopic/drug therapy , Dermatologic Agents/therapeutic use , Facial Dermatoses/drug therapy , Isoleucine/therapeutic use , Leucine/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Ceramides/administration & dosage , Child, Preschool , Dermatologic Agents/administration & dosage , Drug Combinations , Emollients/therapeutic use , Female , Humans , Infant , Leucine/administration & dosage , Male , Skin Cream/therapeutic use , Treatment Outcome
7.
Br J Cancer ; 110(1): 199-207, 2014 Jan 07.
Article in English | MEDLINE | ID: mdl-24196791

ABSTRACT

BACKGROUND: Survivin is detected in few adult normal cells and it is highly expressed in cancer. Nuclear survivin facilitates cell cycle entry, whereas the mitochondrial pool protects cells from apoptosis. Survivin is overexpressed in keratinocyte stem cells (KSCs) and protects them from apoptosis. METHODS: As KSCs are at the origin of squamous cell carcinoma (SCC), we evaluated survivin expression in normal and cancerous skin in vivo by immunohistochemistry and western blotting. HaCaT cells overexpressing survivin and wound-healing assay are used. Analysis of variance and Student's T-tests are used for statistical analysis. RESULTS: Survivin is localised in both the cytoplasm and nucleus of normal adult and young keratinocytes. Nuclear survivin is detected in one every 10 of 11 basal keratinocytes. When present in suprabasal cells, nuclear survivin is coexpressed with K10 but not with K15 or p75-neurotrophin receptor (p75NTR), a transit amplifying cell marker. Nuclear, but not cytoplasmic, survivin expression markedly increases in actinic keratosis and in SCC in situ, as compared with normal epidermis, and it is highest in poorly differentiated SCC. In SCC tumours, nuclear survivin-positive cells are mainly K10/p75NTR-negative and K15-positive. In poorly differentiated tumours, survivin mostly localises in the deep infiltrating areas. When overexpressed in keratinocytes, survivin increases cell migration. CONCLUSION: High survivin expression and the subcellular localisation of survivin correlate with keratinocyte differentiation and are associated with undifferentiated and more invasive SCC phenotype.


Subject(s)
Carcinoma, Squamous Cell/metabolism , Inhibitor of Apoptosis Proteins/biosynthesis , Skin Neoplasms/metabolism , Skin/metabolism , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/pathology , Cell Lineage , Cell Nucleus/metabolism , Child , Child, Preschool , Humans , Infant , Infant, Newborn , Keratinocytes/metabolism , Middle Aged , Neoplasm Invasiveness , Neoplasm Proteins/biosynthesis , Skin Neoplasms/pathology , Survivin , Young Adult
8.
G Ital Dermatol Venereol ; 148(6): 693-8, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24442053

ABSTRACT

Eryfotona AK-NMSC (ISDIN Spain) is a film-forming medical device in cream or fluid formulation containing the DNA-repair enzyme photolyase and high-protection UV filters in liposomes (repairsomes) indicated in the treatment of cancerization field in patients with actinic keratosis (AK) or non-melanoma skin cancer (NMSC). Photolyase is an enzyme that recognizes and directly repairs UV-induced DNA damage. The most common UV-induced DNA damage is the formation of cyclobutane pyrimidine dimers (CPD). Clinical studies evaluating the histological and cellular effects of Eryfotona AK-NMSC have shown a potential benefit in the treatment of the cancerization field in AK patients. In particular the use of Eryfotona AK-NMSC improves the confocal microscopic appearance of skin at the cancerization field level. In addition, Eryfotona AK-NMSC improves the p53 gene expression at keratinocyte level. In this study we reported a series of 6 cases of patients with AK or NMSC lesions treated with Eryfotona AK-NMSC fluid, both as coadjuvant and as single treatment, applied twice daily in the affected area with photograph documentation. Clinical photographs of the skin lesions at baseline and after Eryfotona AK-NMSC treatment were taken in all cases using a high-definition digital camera. Six patients with multiple AK lesions of the scalp or face with or without NMSC were treated for a mean of 1-3 months with Eryfotona AK-NMSC fluid formulation. Image documentations before and after treatment of this clinical series show a great improvement in AK lesions count and of cancerization field. This clinical series supports the clinical efficacy of the use of photolyase and high-protection UV filters in the treatment of cancerization field and AK lesions in patients with actinic damage.


Subject(s)
Anticarcinogenic Agents/therapeutic use , Carcinoma, Squamous Cell/drug therapy , Cell Transformation, Neoplastic/drug effects , Deoxyribodipyrimidine Photo-Lyase/therapeutic use , Keratosis, Actinic/drug therapy , Scalp/drug effects , Skin Neoplasms/drug therapy , Sunscreening Agents/therapeutic use , Aged , Anticarcinogenic Agents/administration & dosage , Carcinoma, Squamous Cell/enzymology , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/pathology , Deoxyribodipyrimidine Photo-Lyase/administration & dosage , Deoxyribodipyrimidine Photo-Lyase/metabolism , Ear/pathology , Face/pathology , Follow-Up Studies , Genes, p53/drug effects , Humans , Keratinocytes/drug effects , Keratinocytes/metabolism , Keratosis, Actinic/enzymology , Keratosis, Actinic/genetics , Keratosis, Actinic/pathology , Liposomes , Male , Middle Aged , Scalp/pathology , Skin Neoplasms/enzymology , Skin Neoplasms/genetics , Skin Neoplasms/pathology , Sunscreening Agents/administration & dosage , Sunscreening Agents/metabolism , Time Factors , Treatment Outcome , Tumor Suppressor Protein p53/drug effects , Tumor Suppressor Protein p53/metabolism
9.
Radiol Med ; 84(1-2): 85-91, 1992.
Article in Italian | MEDLINE | ID: mdl-1509152

ABSTRACT

In order to investigate the value of MRI in the staging of renal cell carcinoma and to compare the results of MRI and CT, the authors evaluated by means of MRI and CT 42 patients affected with renal cell carcinoma. All patients underwent surgery, and pathology of the surgical specimens was performed. A comparison was made between the surgical and pathologic data and MRI and CT results. Moreover, a comparative evaluation of MRI and CT findings was also made. From the comparison between pathologic data and CT and MRI results MRI was seen to have correctly staged 36 of 42 cases (85%), versus CT 33 of 42 cases (78%). Moreover, MRI proved to be superior to CT in evaluating venous involvement (stages III A and III C) and extra-fascial tumor spread (stage IVA). On the contrary, no significant differences were found between MRI and CT in the evaluation of perirenal involvement (stages I-II) and lymph node metastases (stage III B). MRI misdiagnosed 6 of 42 cases: 2 false negatives in evaluating extracapsular tumor spread, 1 false positive of mesenteric infiltration, 1 false positive of renal vein thrombosis, 1 false positive and 1 false negative in evaluating lymph node metastases. CT misdiagnoses (9 of 42 cases) were the same as those of MRI in 5 cases, while in the MRI false positive of renal vein thrombosis CT was correct. The extant 4 incorrect CT findings were: 2 false positive of renal vein thrombosis, 1 false negative of infiltration of diaphragm and psoas muscle, 1 false positive infiltration of the right liver lobe. As yet, therefore, MRI cannot be routinely employed to stage all renal cancer patients. On the contrary, MRI should be considered as a second-choice diagnostic tool to employ in selected cases when CT alone cannot solve all the problems relative to staging.


Subject(s)
Carcinoma/pathology , Kidney Neoplasms/pathology , Magnetic Resonance Imaging , Tomography, X-Ray Computed , Adult , Aged , Aged, 80 and over , Carcinoma/diagnostic imaging , Diagnostic Errors , Evaluation Studies as Topic , False Negative Reactions , False Positive Reactions , Female , Humans , Kidney Neoplasms/diagnostic imaging , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Staging
SELECTION OF CITATIONS
SEARCH DETAIL
...